On the basis of pre-clinic evidence indicating that inhibition of HER2 increases radiation sensitivity of breast cancers [13–15, 35], a combination treatment with radiation and HER2 inhibitors (trastuzumab or lapatinib) is currently under investigation in clinical trials [36]. The gene discussed is ERBB2; the disease is breast cancer.